285983-48-4 | 3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea

317806-87-4    317806-88-5    285983-48-4 

[1]Patent:US2012/184735,2012,A1,.Locationinpatent:Page/Pagecolumn37

5720-05-8    142-71-2    285983-48-4 

[1]Patent:US2002/123631,2002,A1,

75-44-5    285984-25-0    317806-90-9    285983-48-4 

[1]Patent:US2003/232865,2003,A1,.Locationinpatent:Page34-35

317806-87-4    285983-48-4 

[1]Patent:US2004/33222,2004,A1,

5720-05-8    613-33-2    285983-48-4 

[1]TetrahedronLetters,2010,vol.51,#34,p.4547-4551

499972-03-1    317806-90-9    285983-48-4 

[1]Regan,John;Moss,Neil;Pargellis,Chris;Pav,Sue;Proto,Alfred;Swinamer,Alan;Tong,Liang;Torcellini,Carol;Breitfelder,Steffen;Cirillo,Pier;Gilmore,Thomas;Graham,AnneG.;Hickey,Eugene;Klaus,Bernhard;Madwed,Jeffrey;Moriak,Monica[JournalofMedicinalChemistry,2002,vol.45,#14,p.2994-3008]

75-44-5    317806-90-9    317806-86-3    285983-48-4    850312-02-6 

[1]Latli,Bachir[Journaloflabelledcompoundsandradiopharmaceuticals,2004,vol.47,#12,p.847-856]

59997-51-2    285983-48-4 

[1]Regan,John;Moss,Neil;Pargellis,Chris;Pav,Sue;Proto,Alfred;Swinamer,Alan;Tong,Liang;Torcellini,Carol;Breitfelder,Steffen;Cirillo,Pier;Gilmore,Thomas;Graham,AnneG.;Hickey,Eugene;Klaus,Bernhard;Madwed,Jeffrey;Moriak,Monica[JournalofMedicinalChemistry,2002,vol.45,#14,p.2994-3008]

[2]CurrentPatentAssignee:TORAYINDUSTRIESINC-US2012/184735,2012,A1

2834-90-4    285983-48-4 

[1]Regan,John;Moss,Neil;Pargellis,Chris;Pav,Sue;Proto,Alfred;Swinamer,Alan;Tong,Liang;Torcellini,Carol;Breitfelder,Steffen;Cirillo,Pier;Gilmore,Thomas;Graham,AnneG.;Hickey,Eugene;Klaus,Bernhard;Madwed,Jeffrey;Moriak,Monica[JournalofMedicinalChemistry,2002,vol.45,#14,p.2994-3008]

637-60-5    285983-48-4 

[1]Regan,John;Moss,Neil;Pargellis,Chris;Pav,Sue;Proto,Alfred;Swinamer,Alan;Tong,Liang;Torcellini,Carol;Breitfelder,Steffen;Cirillo,Pier;Gilmore,Thomas;Graham,AnneG.;Hickey,Eugene;Klaus,Bernhard;Madwed,Jeffrey;Moriak,Monica[JournalofMedicinalChemistry,2002,vol.45,#14,p.2994-3008]

[2]CurrentPatentAssignee:TORAYINDUSTRIESINC-US2012/184735,2012,A1

Title: Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.

Journal: Journal of medicinal chemistry 20150423

Title: Defining a role for acid sphingomyelinase in the p38/interleukin-6 pathway.

Journal: The Journal of biological chemistry 20140808

Title: Gene expression profiles in engineered cardiac tissues respond to mechanical loading and inhibition of tyrosine kinases.

Journal: Physiological reports 20131001

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2H)-one (AS1940477), a potent p38 MAP kinase inhibitor.

Journal: Journal of medicinal chemistry 20120913

Title: Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.

Journal: Journal of medicinal chemistry 20120809

Title: Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.

Journal: Bioorganic & medicinal chemistry letters 20120801

Title: p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes.

Journal: Blood 20120301

Title: Rational approaches to improving selectivity in drug design.

Journal: Journal of medicinal chemistry 20120223

Title: Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.

Journal: European journal of medicinal chemistry 20120201

Title: Discovery of novel orally active anti-inflammatory N-phenylpyrazolyl-N-glycinyl-hydrazone derivatives that inhibit TNF-α production.

Journal: PloS one 20120101

Title: Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.

Journal: Journal of chemical information and modeling 20111227

Title: Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.

Journal: Nature chemical biology 20111225

Title: Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).

Journal: Bioorganic & medicinal chemistry letters 20111201

Title: Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.

Journal: Journal of medicinal chemistry 20111124

Title: 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.

Journal: Journal of medicinal chemistry 20111124

Title: Indolin-2-one p38α inhibitors III: bioisosteric amide replacement.

Journal: Bioorganic & medicinal chemistry letters 20111101

Title: Comprehensive analysis of kinase inhibitor selectivity.

Journal: Nature biotechnology 20111030

Title: A possible mechanism for hepatotoxicity induced by BIRB-796, an orally active p38 mitogen-activated protein kinase inhibitor.

Journal: Journal of applied toxicology : JAT 20111001

Title: Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

Journal: ChemMedChem 20110905

Title: Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease.

Journal: The Journal of pharmacology and experimental therapeutics 20110901

Title: Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

Journal: European journal of medicinal chemistry 20110601

Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Journal: Chemistry & biology 20101124

Title: Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.

Journal: Bioorganic & medicinal chemistry letters 20101001

Title: X-ray crystal structure of JNK2 complexed with the p38alpha inhibitor BIRB796: insights into the rational design of DFG-out binding MAP kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20100901

Title: The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.

Journal: Bioorganic & medicinal chemistry 20100801

Title: Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

Journal: Biochemistry 20100504

Title: Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin-6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells.

Journal: The Journal of pharmacology and experimental therapeutics 20100401

Title: Displacement assay for the detection of stabilizers of inactive kinase conformations.

Journal: Journal of medicinal chemistry 20100114

Title: Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1.

Journal: Toxicology and applied pharmacology 20090715

Title: A new screening assay for allosteric inhibitors of cSrc.

Journal: Nature chemical biology 20090601

Title: Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.

Journal: The Journal of biological chemistry 20090508

Title: Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20090501

Title: Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage.

Journal: The Biochemical journal 20090315

Title: Inhibition of p38: has the fat lady sung?

Journal: Arthritis and rheumatism 20090201

Title: Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.

Journal: Bioorganic & medicinal chemistry letters 20080801

Title: Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region.

Journal: Journal of medicinal chemistry 20080724

Title: Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells.

Journal: Bioorganic & medicinal chemistry letters 20080701

Title: Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.

Journal: Bioorganic & medicinal chemistry letters 20080601

Title: The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters 20080315

Title: A quantitative analysis of kinase inhibitor selectivity.

Journal: Nature biotechnology 20080101

Title: The selectivity of protein kinase inhibitors: a further update.

Journal: The Biochemical journal 20071215

Title: New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.

Journal: Bioorganic & medicinal chemistry letters 20070801

Title: Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.

Journal: Haematologica 20070401

Title: p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage.

Journal: Hypertension (Dallas, Tex. : 1979) 20070301

Title: BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

Journal: British journal of haematology 20070201

Title: The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures.

Journal: Respiratory research 20070101

Title: Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.

Journal: Journal of medicinal chemistry 20061228

Title: Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.

Journal: Bioorganic & medicinal chemistry letters 20061215

Title: Microwave-assisted synthesis of N-pyrazole ureas and the p38alpha inhibitor BIRB 796 for study into accelerated cell ageing.

Journal: Organic & biomolecular chemistry 20061121

Title: Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery.

Journal: Analytical biochemistry 20060915

Title: Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.

Journal: Assay and drug development technologies 20060801

Title: Rational design of inhibitors that bind to inactive kinase conformations.

Journal: Nature chemical biology 20060701

Title: BIRB-796 is not an effective ABL(T315I) inhibitor.

Journal: Nature biotechnology 20051001

Title: Features of selective kinase inhibitors.

Journal: Chemistry & biology 20050601

Title: BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo.

Journal: The Journal of biological chemistry 20050520

Title: HierS: hierarchical scaffold clustering using topological chemical graphs.

Journal: Journal of medicinal chemistry 20050505

Title: A small molecule-kinase interaction map for clinical kinase inhibitors.

Journal: Nature biotechnology 20050301

Title: P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia.

Journal: Journal of clinical immunology 20040101

Title: Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.

Journal: Journal of medicinal chemistry 20031023

Title: Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).

Journal: Journal of medicinal chemistry 20031023

Title: The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

Journal: Bioorganic & medicinal chemistry letters 20030915

Title: Anti-arthritic agents--SMi conference: trapping cytokines. 28-29 April 2003, London, UK.

Journal: IDrugs : the investigational drugs journal 20030601

Title: Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.

Journal: Journal of medicinal chemistry 20020704

Title: Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.

Journal: Nature structural biology 20020401

Title: Dietrich J, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5738-48

Title: Cicenas J, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017 Dec 21;10(1). pii: E1.

Title: Kuma Y, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 2005, 280(20), 19472-19479.

Title: He D, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 2013;8(1):e54181.

Title: Park JK, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007 Mar;49(3):481-9.